Health Condition 1: J455- Severe persistent asthma
Conditions
Sponsors
Dr Randeep Guleria
Dr Anant Mohan
Dr Saurabh Mittal
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with physician-diagnosed severe asthma 2. Age > 18 yrs 3. Planned to receive Benralizumab therapy 4. Patients ready to give consent
Exclusion criteria
Exclusion criteria: Not giving written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effect of benralizumab therapy on ACT score at 6 months of therapyTimepoint: To assess the effect of benralizumab therapy on ACT score at 6 months of therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| ï?® To assess the effect of benralizumab therapy on AQLQ, SGRQ and HADS at 6 months of therapyTimepoint: 6 months;To assess the effect of benralizumab therapy on AHI during sleep study at 6 months of therapyTimepoint: 6 months;To assess the effect of benralizumab therapy on air-trapping as assessed by CT chest at 6 months of therapyTimepoint: 6 months;To assess the effect of benralizumab therapy on AQLQ score at 6 months of therapyTimepoint: 6 months;To assess the effect of benralizumab therapy on inflammatory markers (LDH, Ferritin) at 6 months of therapyTimepoint: 6 months;To assess the effect of benralizumab therapy on lung function (pre BD FEV1, RV, TLC and RV/TLC) at 6 months of therapyTimepoint: 6 months;To assess the effect of benralizumab therapy on Sleep related quality of life at 6 months of therapyTimepoint: 6 months | — |
Countries
India
Contacts
Public ContactSaurabh Mittal
AIIMS, New Delhi
Outcome results
None listed